



Adaptive protocols based on predictions from a mechanistic model of the effect of IL7 on CD4 counts

Laura Villain, Daniel Commenges, Mélanie Prague, Chloé Pasin, Rodolphe Thiébaut

► To cite this version:

Laura Villain, Daniel Commenges, Mélanie Prague, Chloé Pasin, Rodolphe Thiébaut. Adaptive protocols based on predictions from a mechanistic model of the effect of IL7 on CD4 counts. International Biometric Conference, Jul 2018, Baelone, Spain. hal-01973877

HAL Id: hal-01973877

<https://inria.hal.science/hal-01973877>

Submitted on 8 Jan 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Adaptive protocols based on predictions from a mechanistic model of the effect of IL7 on CD4 counts

L. Villain^{1,2,3*}, D. Commenges^{1,2,3}, M. Prague^{1,2,3}, C. Pasin^{1,2,3}, R. Thiébaut^{1,2,3}

¹INRIA Bordeaux Sud-Ouest, SISTM team, Talence, France

²Univ. Bordeaux, centre INSERM U1219 BPH, Bordeaux, France

³Vaccine Research Institute, Créteil, France


IBC, Barcelona, July 2018



Introduction and context

- Some HIV-infected patients are unable to restore their levels of CD4 + T cells (CD4).
- IL7 is a cytokine produced by the organism (stromal cells).
- Injections of IL7 could help the reconstitution of the immune system.
- The aim is to maintain the patient above 500 CD4/ μ L of blood.

- The first clinical trial on IL7 show positive results (Sereti Blood 2009, Levy CID 2012, Levy JCI 2009).



- Repeated cycle are necessary.
- Best adaptive protocol yet to determine.

- Data from phase I / II trials : INSPIRE 1, 2 and 3.
- 138 HIV-infected patients.
- Regular measurements of immunologic markers.




Figure – Design of INSPIRE 2 and 3 studies (**ORI** protocol)

Mechanistic model

- Model the different cell populations, as shown in the following figure with the CD4 population.




Figure – P : proliferative CD4, R : resting CD4

$$\begin{cases} \frac{dR}{dt} = \lambda - \pi R + 2\rho P - \mu_R R, \\ \frac{dP}{dt} = \pi R - \rho P - \mu_P P, \end{cases} \quad (1)$$

- λ is the cell production rate, π is the proliferating rate, ρ is the return to resting state rate, μ_R is the death rate of resting cells and μ_P is the death rate of proliferative cells.

Summary of the model

- **Mechanistic model** with biological parameters : one set of parameters means one trajectory
- Effect of the IL7 on the proliferation (π) and cellular death (μ_R)
- **Random effects** on the production and reversion rates (λ and ρ)
- There is a **measurement error**

Estimation by NIMROD

Table – Parameters of the model and their estimation from Jarne et al. 2018

Parameter	Name	Units	Estimation
λ	Production rate	days ⁻¹	5.32 (0.33)
ρ	Reversion rate	cells.days ⁻¹	2.44 (0.23)
π	Proliferation rate	cells.days ⁻¹	0.058 (0.004)
μ_P	Death rate of P cells	cells.days ⁻¹	0.074 (0.005)
μ_R	Death rate of R cells	cells.days ⁻¹	0.077 (0.015)
β_{π_1}	Effect of IL7 on π (Inj1)	days ⁻¹ . μg^{-1}	0.93 (0.04)
β_{π_2}	Effect of IL7 on π (Inj2)	days ⁻¹ . μg^{-1}	0.707 (0.04)
β_{π_3}	Effect of IL7 on π (Inj3)	days ⁻¹ . μg^{-1}	0.229 (0.04)
β_{μ_R}	Effect of IL7 on μ_R	cells.days ⁻¹ . μg^{-1}	-0.08 (0.006)
β_C	Cycle effect of IL7	days ⁻¹	-0.163 (0.015)
σ_λ	sd of the random effect on λ	days ⁻¹	0.243 (0.026)
σ_ρ	sd of the random effect on ρ	cells.days ⁻¹	0.515 (0.084)
σ_{CD4}	Error of measurement on CD4	cells ^{0.25}	0.289 (0.003)
σ_P	Error of measurement on P	cells ^{0.25}	0.281 (0.019)




Figure – Evolution of the total number of CD4 cells (cells/ μ L) on a patient after IL7 injections. Black line : fit predicted by NIMROD. Red dots : observations. Red lines : injections times.

Adaptive Protocols.

The criterion of 550 CD4 for a new injection is **not adapted** to the patient :


- For those with a fast decrease of CD4 after an injection, the limit might be **too low** and then they risk to spend too much **time under 500 CD4**
- For those with a slow decrease of CD4 after an injection, the limit might be **too high** and then have **unnecessary cycles of injection**

To solve those issues, we propose **four adaptive protocols**.


- We want to keep the level of CD4 **above the level of** $500\text{CD4}/\mu\text{L}$ **of blood**, but without too many injections.
- A **mechanistic model** was developed to show the effect of IL7 on the population of CD4 T cells.
- With this model, we use an MCMC algorithm to estimate the **individual parameters to personalized the IL7 injections**.

We have **two ways of optimizing** :


- We can still keep a **visit every 3 month** and predict the **risk to be under 500 CD4** at the next visit. (Adaptive Criterion of Injection = **ACI**).
- Or we can predict the time when the patient will be at 500 CD4 and **adapt the time of the next visit**. (Adaptive Time of Injection = **ATI**).




Method




**Protocol
ORI**




**Protocol
ACI**




**Protocol
ORI**




**Protocol
ATI**



**Protocol
ORI**




**Protocol
ACI**




Results

**Protocol
ORI**




**Protocol
ATI**




Results

**Time spent under 500 CD4
for each protocols**



**Number of injections
for each protocols**



Adaptive protocols

Data and protocols
MCMC
Protocols parameters

Time


CD4

Ki67

Injections

Time	CD4	Ki67	Injections
0.00	450.00	10.00	1.00
7.00	700.00	12.00	1.00
14.00	950.00	18.00	1.00
90.00	740.00	11.00	0.00

Visit time



Adaptive protocols

Data and protocols
MCMC
Protocols parameters

Time

CD4

Ki67


Injections

UPLOADI

Time	CD4	Ki67	Injections
0.00	450.00	10.00	1.00
7.00	700.00	12.00	1.00
14.00	950.00	18.00	1.00
90.00	740.00	11.00	0.00

Visit time

Calculate




Decision ACI: Pas d'injection, prochaine visite dans 3 mois
 Decision ACIC: Pas d'injection, prochaine visite dans 3 mois
 Decision ATI: Pas d'injections, visite dans 99 jours
 Decision ATIC: Pas d'injections, visite dans 99 jours

Conclusion and Perspectives


- The adaptive protocols showed a **strong diminution of the time spent under 500** without an increase of the number of injections.
- Shiny app under development to have an easy interface.
- This protocol could be **tested in a clinical trial**.

Thank you for your attention

Evolution of the estimation of Lambda







Evolution of the estimation of rho



- For the patient i , each iteration q of the MCMC gives a couple $(\lambda_q, \rho_q)_i$
- Each couple of parameters gives a trajectory of CD4 :
$$\text{CD4}_{i,q}(t) = [P(t, \xi^{i,q}) + Q(t, \xi^{i,q})]$$
- At each time point t_{ij} we have the distribution of CD4 and the distribution of the observations by adding an error of measurement : $Y_{1jq}^i = [P(t_{ij}, \xi^{i,q}) + Q(t_{ij}, \xi^{i,q})]^{0.25} + \epsilon_{1jq}^i$

Prediction ability on real patients



Prediction ability on real patients

